Primary Immunodeficiency Diseases (PID)
25
2
3
19
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 17/100
0.0%
0 terminated out of 25 trials
100.0%
+13.4% vs benchmark
40%
10 trials in Phase 3/4
53%
10 of 19 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 19 completed trials
Clinical Trials (25)
A Database Survey to Evaluate the Safety of Immune Globulin Subcutaneous (Human), 20% Solution in Participants With Primary Immunodeficiency
Virtual Reality on Pain and Fear Levels of Children With Primary Immunodeficiency
A Study to Evaluate the Long-term Safety of TAK-771 in Japanese Primary Immunodeficiency Disease (PID) Participants
A Study About the Long-Term Safety of TAK-881 in People With Primary Immunodeficiency Diseases
A Study About How TAK-881 is Processed by the Body and Side Effects in People With Primary Immunodeficiency Diseases
Ex Vivo Evaluation of JAK-inhibitor and Gene Therapeutical Approach in JAK-STAT Related Disorders
At-Home Subcutaneous Immunoglobulin Replacement Therapy Using Alexa Skill
Efficacy, Safety and Pharmacokinetic of Virchow IVIG in PID Patients
A Study of TAK-771 in Japanese People With Primary Immunodeficiency Diseases (PID)
Inbon Errors of Immunity Attending Assiut University Children&Amp;#39;s Hospital: a Single Center Study
A Study of Immune Globulin Subcutaneous (Human), 20% Solution (IGSC, 20%) in Japanese Participants With Primary Immunodeficiency Diseases (PID)
Efficacy, Safety, Tolerability, Immunogenicity and Pharmacokinetic Evaluation of HYQVIA in Pediatric PIDD Subjects
Evaluation of Subcutaneous Immunoglobulin Product Cutaquig in Terms of Safety and Efficacy in the Treatment of Patients With Primary Immunodeficiencies
Post-Authorization Safety, Tolerability and Immunogenicity Evaluation of HyQvia in Pediatric PIDD Subjects
Non-Interventional Post-Marketing Safety Study on the Long-Term Safety of HYQVIA (Global)
Safety, Pharmacokinetic and Efficacy Study of a 10% Triple Virally Reduced Intravenous Immune Globulin Solution in Patients With Primary Immunodeficiency (Hypo- or Agammaglobulinemia)
Safety and Efficacy Study of a 10% Intravenous Immune Globulin Solution in Subjects With Primary Immunodeficiency Disorders
Phase 2/3 Study of IGSC, 20% in PIDD
Tolerability and Safety of Immune Globulin Subcutaneous Solution (IGSC) and rHuPH20 in PID
Tolerability and Safety of IGI, 10% With rHuPH20 in PIDD